Cargando…
Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs
Alzheimer’s disease (AD) is the most common age-dependent neurodegenerative disease which impairs cognitive function and gradually causes patients to be unable to lead normal daily lives. While the etiology of AD remains an enigma, excessive accumulation of β-amyloid peptide (Aβ) is widely believed...
Autor principal: | Yan, Riqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944430/ https://www.ncbi.nlm.nih.gov/pubmed/27418961 http://dx.doi.org/10.1186/s40035-016-0061-5 |
Ejemplares similares
-
Role of BACE1 in Alzheimer’s synaptic function
por: Das, Brati, et al.
Publicado: (2017) -
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
por: Vassar, Robert
Publicado: (2014) -
One Step Closer: Nontuberculous Mycobacterial Pulmonary Disease and Predicted Mortality—The BACES Score
por: Aksamit, Timothy R.
Publicado: (2021) -
BACE1 Inhibitors for Alzheimer’s Disease: The Past, Present and Any Future?
por: Bazzari, Firas H., et al.
Publicado: (2022) -
Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment
por: Coimbra, Judite R. M., et al.
Publicado: (2018)